Compare ARK Genomic Revolution ETF (ARKG) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Las Vegas Sands Corp. — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Las Vegas Sands Corp. trades at $46.62 (market cap $30.94B). The key difference: Las Vegas Sands Corp. pays a 2.36% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Las Vegas Sands Corp. nearer its low. Which is the better fit depends on your goals.
| ARKG | LVS | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $69.49 |
52-Week Low | $23.09 | $46.06 |
Market Cap | — | $30.94B |
Enterprise Value | — | $43.33B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
LVS trades at $46.69, up 0.52% with a bearish technical signal despite strong fundamentals. The company demonstrates robust revenue growth, reaching $13.02B in 2025 with consistent earnings beats and a 13.41% net margin. Analyst consensus remains strongly bullish with a $66.89 price target, though technical indicators show selling pressure with support at $46.
LVS presents a compelling investment case with strong operational performance and analyst support, though technical weakness and high debt levels pose risks. The stock offers significant upside potential from current levels if fundamental strength continues, but investors should monitor debt management and Macau market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
